Skip to main content

ABCD Nationwide Canagliflozin Audit Publications

Papers, abstracts, presentations, posters and webcasts emanating from the audit

Webcast

Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD audits research fellow, Dr Thomas Crabtree at EASD 2021:
Sodium-glucose linked transporter 2 inhibitors (SGLT2s) and alanine aminotransferase levels (ALT) in the Associated of British Clinical Diabetologists (ABCD) audits - Virtual Meeting | EASD

Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD audits research fellow, Dr Thomas Crabtree at EASD 2021:
P230: The effect of sodium-glucose link transporter 2 inhibitors (SGLT2i) on microalbuminuria: cross-class analysis from the ABCD audit programme

Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD audits research fellow, Dr Thomas Crabtree at DUK Professional Conference 2021:
Comparing the effects of different-sodium glucose link-transporter 2-inhibitors (SGLT2i) on HbA1c an weight in the real world: updated analysis from the Association of British Clinical Diabetologists (ABCD) Audit Programmes

Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD audits research fellow, Dr Thomas Crabtree at DUK Professional Conference 2021:
The impact of sodium glucose link transporter-2 inhibitors [SGLT2i] on Fib4 score in patients with type 2 diabetes: Analysis using Association of British Clinical Diabetologists [ABCD] nationwide audit data

Webcast of an ePoster presentation of the results from the ABCD nationwide canagliflozin audit presented by ABCD audits research fellow, Dr Thomas Crabtree at the ADA Virtual Meeting ADA 2020:
Effect of Canagliflozin on Alanine Aminotransferase (ALT): ABCD Nationwide Canagliflozin Audit

Webcast of an ePoster presentation of the results by Dr Harshal Deshmukh from Hull, UK, reporting data from the ABCD nationwide audits of SGLT2 inhibitors in real clinical use in the UK, made at the American Diabetes Association virtual meeting in June 2020:
Effect Of Raised Alanine Transaminase (ALT) On HbA1c Response to SGLT2 Inhibitors In Type 2 Diabetes

Webcast of an ePoster presentation of the results from the ABCD nationwide canagliflozin audit presented by Dr Bob Ryder at the ADA in San Francisco in June 2019:
Results from the ABCD nationwide canagliflozin audit

 

Published papers

Crabtree TSJ, Winocour P, Darzy K, Phillips S, Evans A, Rohilla A, Raghavan R, Sennik D, Bickerton A, Idris I, Yadagiri M, Ryder REJ, ABCD Canagliflozin Audit Contributors. Effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit. BJD Vol 20, No 2 (2020) Pages 113-116.

Abstract   Br J Diabetes 2020;20:2:113-116  

Full Text Br J Diabetes 2020;20:2:113-116 

All contributors are listed 
 

Slides from presentations

DUK Professional Conference, Virtual March 2021
EASD 2022 SGLT2 Slides

 

Abstracts

EASD Lisbon, 2017 M Yadagiri, A Robinson, K Darzy, P Winocour, A Strzelecka, IW Gallen, A Bickerton, S Phillips, A Evans, REJ Ryder and ABCD Nationwide Canagliflozin audit contributors. One year metabolic outcomes in the ABCD nationwide canagliflozin audit. Poster presentation 871. Diabetologia 2017, Vol.60 Supplement1: Abstract 871

EASD Berlin, 2018 A Puttana, M Yadagiri, P Sen Gupta, I Gallen, A Bickerton, S Phillips, A Evans, D Sennik, R Ryder  2 year metabolic outcomes in the ABCD nationwide canagliflozin audit.Diabetologia 2018, Vol.61 Supplement1: Abstract 637

DUK Liverpool, 2019 A Puttanna, M Yadagiri, P Sen Gupta, IW Gallen, A Bickerton, S Phillips, A Evans, Sennik, REJ Ryder and ABCD nationwide canagliflozin audit contributors. Two year metabolic outcomes in the Association of British Clinical Diabetologist (ABCD) Nationwide Canagliflozin Audit: a comparison of glycaemic improvements. Poster Presentation A comparison of glycaemic improvements, Diabetic Medicine 2019. 36 (Suppl 1): Abstract A3. (P115)

ADA, San Fransisco 2019 R E.J. Ryder, S M. Phillips, A Evans, D K. Sennik, A Rohilla, A Bickerton, K Thong, M Yadagiri, M L. Cull, M C. Wyres, P Winocour, K H. Darzy, A Strzleka, S G. Gohil, A Gallagher, I W. Gallen, Relationship Between Canagliflozin Treatment Response and Duration of Diabetes: The Association of British Clinical Diabetologists (ABCD) Nationwide Canagliflozin Audit. Diabetes 2019 Jun; 68 (Supplement 1): 1209-P.

ADA, Virtual Meeting TC, 2020 Thomas S.J. Crabtree, Suzanne M. Phillips, Alison Evans, Devesh K. Sennik, Anurita Rohilla, Alex Bickerton, Ken H. Darzy, Peter Winocour, Melissa L. Cull, Anna Strzelecka, Rajeev P. Raghavan, Ian W. Gallen, Mahender Yadagiri and Robert E. Ryder. The Effect of Canagliflozin on Alanine Aminotransferase (ALT) Levels: Data from the Association of British Clinical Diabetologists (ABCD) Nationwide Audit Programme

ADA Virtual Meeting HD, 2020 - Harshal Deshmukh, Alex Bickerton, Suzanne M. Phillips, Alison Evans, Rajeev P. Raghavan, Devesh K. Sennik, Anurita Rohilla, Karen Adamson, Mahender Yadagiri, Ian W. Gallen, Robert E. Ryder and Thozhukat Sathyapalan. Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 Inhibitors (SGLT2i) - Diabetes 2020 Jun; 69(Supplement 1):1110-P

DUK London TC1, 2021 Crabtree, T. S. J., J. Elliott, S. Sivappriyan, D. Barnes, A. Bickerton, I. Gallen, I. Idris, and R. E. J. Ryder. "The impact of sodium glucose link transporter-2 inhibitors (SGLT2i) on Fib4 score in patients with type 2 diabetes: Analysis using Association of British Clinical Diabetologists (ABCD) nationwide audit data." In DIABETIC MEDICINE, vol. 38. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021.

DUK London TC2, 2021 Crabtree, T. S. J., K. Dhatariya, A. Bickerton, S. Sivappriyan, D. Barnes, S. Tarpey, S. Rowles, K. Adamson, I. Gallen, and R. E. J. Ryder. "Comparing the effects of different sodium-glucose link transporter 2 inhibitors (SGLTi) on HbA1c and weight in the real world: updated analysis from the Association of British Clinical Diabetologists (ABCD) audit programmes." In DIABETIC MEDICINE, vol. 38. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021.

EASD Virtual Meeting, 2021 Gallen, I., T. S. J. Crabtree, A. Gallagher, K. Dhatariya, A. Bickerton, J. Elliott, G. Rayman, and R. E. J. Ryder. "Sodium-glucose linked transporter 2 inhibitors (SGLT2s) and alanine aminotransferase levels (ALT) in the Associated of British Clinical Diabetologists (ABCD) audits." In DIABETOLOGIA, vol. 64, no. SUPPL 1, pp. 218-218. ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES: SPRINGER, 2021.

ADA New Orleans, 2022 Thomas S.J. Crabtree, Alison Gallagher, Siva Sivappriyan, Ketan Dhatariya, Rajeev P. Raghavan, Alex Bickerton, Jackie Elliott, Melissa L. Cull, Gerry Rayman, Ian W. Gallen, Iskandar R. Idris, Robert E. Ryder; 858-P: Predictors of HbA1c and Weight Response to Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) in the Association of British Clinical Diabetologist (ABCD) UK Nationwide Audit. Diabetes 1 June 2022; 71 (Supplement_1): 858–P. https://doi.org/10.2337/db22-858-P

 

Posters 

EASD Lisbon, 2017
EASD Berlin, 2018
DUK Liverpool, 2019
ADA San Fransisco, 2019
ADA Virtual Meeting June, 2020TC
ADA Virtual Meeting June, 2020HD
ABCD Virtual Meeting December 2020TC
ABCD RA Virtual Meeting February 2021TC
Diabetes UK Professional Conference 2021TC
Diabetes UK Professional Conference 2021TC2 
Diabetes UK Professional Conference 2022
ADA 2022
 


 

 

 

The ABCD nationwide canagliflozin audit is an independent audit supported by an unrestricted grant from Janssen